Company news
Jiangsu Aidea Pharmaceutical Group Co., Ltd. news in 2025
Jiangsu Aidea Pharmaceutical Group Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on the Voluntary Disclosure of Renewal and Inclusion of Two Innovative Anti-HIV Drugs in the National Medical Insurance Catalog
December 7, 2025
Announcement on Voluntary Disclosure of the Successful Enrollment of the 1st Subject in the Phase III Clinical Trial of ACC017 Tablets
November 7, 2025
Report for Q3 2025
October 30, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC118 Tablets
October 28, 2025
Announcement on Voluntary Disclosure of Marketing Authorization Approval Received for Dolutegravir Sodium Active Pharmaceutical Ingredient
October 27, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADB116 for Injection
October 24, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
October 15, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025
September 29, 2025
Announcement on Retirement and Resignation of Core Technical Personnel
September 11, 2025
Announcement on Attending Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025
September 4, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Completion of Registration of Initial Grant under 2025 Stock Option Incentive Plan
August 25, 2025
Announcement on Resolutions of the 5th Meeting of the 3rd Board of Directors
August 14, 2025
Announcement on Voluntary Disclosure of Obtaining Zanzibar Drug Registration Certificate for Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
July 27, 2025
Announcement on Completion of Industrial and Commercial Registration for Company Name Change and Business License Renewal
July 21, 2025
Self-Inspection Report on Trading of the Company's Stocks by Insiders and Incentive Objects of Stock Option Incentive Plan 2025
July 14, 2025
Review Opinions of the Remuneration and Appraisal Committee of the Board of Directors and Public Disclosure of the List of Recipients for the Initial Grant under the Company's 2025 Stock Option Incentive Plan
July 7, 2025
Announcement on Canceling Some Restricted Stocks Granted but Not Yet Vested in the 2022 Restricted Stock Incentive Plan
June 27, 2025